Financial strategy
We continue to benefit from strong cash generation with net cash inflow from operating
activities of over £5 billion, up 6% in sterling terms in the first nine months of this year.
Our financial strategy is focused on maintaining an efficient balance sheet, retaining flexibility
to invest in our strategic priorities and increasing returns to our shareholders through our
progressive dividend policy. This quarter’s dividend increased by 8% to 14 pence and we
have completed share repurchases of £3.3 billion in the 9 months to 30th September 2008.
We expect to have completed around £4 billion of repurchases by the year-end, subject to
market conditions.
With the recent changes in financial markets we now expect more investment opportunities to
arise that will allow us to invest in support of our strategic priorities. To ensure we have
sufficient flexibility to take advantage of these opportunities we do not currently expect to
make significant share repurchases in 2009. Investment opportunities will continue to be
assessed against strict financial criteria.
Iøvrigt bliver OFAB specifikt nævnt iforbindelse med fremskreden fase 3 stoffer
We continue to benefit from strong cash generation with net cash inflow from operating
activities of over £5 billion, up 6% in sterling terms in the first nine months of this year.
Our financial strategy is focused on maintaining an efficient balance sheet, retaining flexibility
to invest in our strategic priorities and increasing returns to our shareholders through our
progressive dividend policy. This quarter’s dividend increased by 8% to 14 pence and we
have completed share repurchases of £3.3 billion in the 9 months to 30th September 2008.
We expect to have completed around £4 billion of repurchases by the year-end, subject to
market conditions.
With the recent changes in financial markets we now expect more investment opportunities to
arise that will allow us to invest in support of our strategic priorities. To ensure we have
sufficient flexibility to take advantage of these opportunities we do not currently expect to
make significant share repurchases in 2009. Investment opportunities will continue to be
assessed against strict financial criteria.
Iøvrigt bliver OFAB specifikt nævnt iforbindelse med fremskreden fase 3 stoffer
GENMAB PRÆSENTERER VED 2008 PIPER JAFFRAY HEALTH CARE KONFERENCE
København, Danmark, 24. november 2008 – Genmab A/S (OMX: GEN) offentliggjorde i dag, at selskabets Chief Financial Officer, David Eatwell vil præsentere ved 2008 Piper Jaffray Health Care Konference i New York City, New York den 2. december kl. 10.00 lokal tid (kl. 16.00 dansk tid). Det er muligt at følge en live webcast af præsentationen via Genmabs hjemmeside www.genmab.com, hvor den efterfølgende også vil være tilgængelig.
København, Danmark, 24. november 2008 – Genmab A/S (OMX: GEN) offentliggjorde i dag, at selskabets Chief Financial Officer, David Eatwell vil præsentere ved 2008 Piper Jaffray Health Care Konference i New York City, New York den 2. december kl. 10.00 lokal tid (kl. 16.00 dansk tid). Det er muligt at følge en live webcast af præsentationen via Genmabs hjemmeside www.genmab.com, hvor den efterfølgende også vil være tilgængelig.
